Advances in the Treatment of Childhood Acute Lymphoblastic Leukemia / 임상소아혈액종양
Clinical Pediatric Hematology-Oncology
; : 12-26, 2019.
Article
de En
| WPRIM
| ID: wpr-763508
Bibliothèque responsable:
WPRO
ABSTRACT
In recent decades, survival rates for childhood acute lymphoblastic leukemia have improved remarkably, as demonstrated by risk-stratified, prospective multicenter studies. Treatment protocols have evolved and become better matched to both prognostic factors and treatment responses. Recently, new molecular prognostic factors have been discovered in leukemia genomic studies. New tumor subtypes with independent gene expression profiles have also been characterized. Furthermore, therapies targeted to specific candidate mutations are being identified to broaden therapeutic options for patients with poor prognoses. Many new drugs are in clinical trials and immunotherapy is attracting significant interest for the treatment of recurrent or refractory disease in childhood acute lymphoblastic leukemia.
Mots clés
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Pronostic
/
Leucémies
/
Protocoles cliniques
/
Taux de survie
/
Études prospectives
/
Leucémie-lymphome lymphoblastique à précurseurs B et T
/
Transcriptome
/
Immunothérapie
Type d'étude:
Clinical_trials
/
Guideline
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limites du sujet:
Humans
langue:
En
Texte intégral:
Clinical Pediatric Hematology-Oncology
Année:
2019
Type:
Article